daclizumab   Click here for help

GtoPdb Ligand ID: 6880

Synonyms: L04AC01 | RO-24-7375 | Ro-247375 | Zenapax®
Approved drug Immunopharmacology Ligand
daclizumab is an approved drug (FDA FDA (1997), EMA (1999))
Compound class: Antibody
Comment: Daclizumab is a monoclonal antibody binding to the α subunit (CD25) of the high-affinity interleukin-2 receptor.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

An advanced version of daclizumab, with identical primary sequence, but which is differentially gylcosylated, called daclizumab beta (BIIB019, DAC HYP) has been developed for subcutaneous administration. Daclizumab beta's alternate glycosylation pattern changes its binding to Fc receptors and reduces its propensity to induce complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).
Click here for help
1. Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E, Boyko A, Kaufman M, Rose J, Greenberg S, Sweetser M et al.. (2015)
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
N Engl J Med, 373 (15): 1418-28. [PMID:26444729]
2. Queen CL, Schneider WP, Selick HE. (1997)
Genetic engineering; complementarity zones.
Patent number: US5693761. Assignee: Protein Design Labs, Inc.. Priority date: 28/12/1988. Publication date: 02/12/1997.
3. Tran JQ, Othman AA, Mikulskis A, Wolstencroft P, Elkins J. (2016)
Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis.
Clin Pharmacol, 8: 9-13. [PMID:26929672]